Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma-Reference-Cited by-同舟云学术

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Published:2016-08 Issue:8 Volume:22 Page:1391-1396
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Rodriguez Tulio E.^ORCID,Hari Parameswaran,Stiff Patrick J.,Smith Scott E.,Sterrenberg Danielle,Vesole David H.

Funder

Otsuka Pharmaceutical Co, Ltd

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference35 articles.

1. Hematopoietic cell transplantation for multiple myeloma;Qazilbash,2004

2. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma;Costa;Biol Blood Marrow Transplant,2013

3. Additive pulmonary toxicity with melphalan and busulfan therapy;Schallier;Chest,1983

4. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma;Lahuerta;Leuk Lymph,2002

5. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study;Lahuerta;Haematologica,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-01-31

2. Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma;British Journal of Haematology;2024-01-04

3. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;2023-09-22

4. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL);American Journal of Hematology;2023-06-19

5. Stem Cell Transplant for Plasma Cell Dyscrasias;Basics of Hematopoietic Stem Cell Transplant;2023